Probiotics and Gut Microbiota Modulation in Obesity

Obesity arises from complex interactions among diet, host genetics, lifestyle and the trillions of microorganisms residing in the gastrointestinal tract. Alterations in the composition and function of this microbial community—termed dysbiosis—can promote increased energy harvest, low-grade inflammation and impaired gut barrier integrity, all recognised as drivers of adiposity and metabolic dysfunction. Probiotics, live microorganisms that confer health benefits when administered in adequate amounts, have emerged as a promising strategy to rectify dysbiosis, modulate host metabolism and ameliorate obesity-related traits. Evidence from preclinical models demonstrates that specific strains can regulate bile acid signalling, attenuate inflammatory cascades and enhance production of short-chain fatty acids (SCFAs), thereby improving lipid and glucose homeostasis. Human trials, though heterogeneous in design and outcome, suggest that multi-strain formulations and synbiotic combinations may yield modest reductions in body mass index and metabolic biomarkers. The global burden of obesity underscores the significance of microbial modulation as an adjunctive therapy, with potential for personalised probiotic regimens tailored to individual microbial fingerprints.

Research from Nature Portfolio

Studies in scientific reports have elucidated mechanistic links between probiotic viability and metabolic improvements. A highly proliferative Bifidobacterium strain was shown to reshape gut community structure, enriching acetate-producing taxa and elevating circulating SCFAs. These changes correlated with reduced visceral adiposity, improved glucose tolerance and enhanced secretion of glucagon-like peptide-1. Metagenomic and metabolomic analyses point to acetate as a key mediator by which specialised strains transmit anti-obesity effects, reinforcing the concept of targeted microbiota modulation to correct metabolic derangements.

Probiotics and Gut Microbiota Modulation in Obesity publication trend

The graph below shows the total number of articles in probiotics and gut microbiota modulation in obesity across all publications each year (not limited to Nature Index journals).

Technical terms

Probiotics: Live microorganisms that, when consumed in adequate amounts, confer health benefits on the host.

Gut microbiota: The community of bacteria, archaea, viruses and fungi inhabiting the gastrointestinal tract.

Dysbiosis: An imbalance in the composition or function of the gut microbial community associated with disease.

Short-chain fatty acids (SCFAs): Metabolites produced by microbial fermentation of dietary fibres, implicated in energy homeostasis and immune regulation.

Farnesoid X receptor (FXR): A nuclear receptor activated by bile acids, regulating lipid and glucose metabolism.

Metabolic endotoxemia: Systemic inflammation triggered by translocation of microbial lipopolysaccharide into circulation.

References

1. Inhibition of intestinal FXR activity as a possible mechanism for the beneficial effects of a probiotic mix supplementation on lipid metabolism alterations and weight gain in mice fed a high fat diet. Gut Microbes (2023).
2. The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence. Advances in Nutrition (2023).
3. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Scientific Reports (2017).